Patent Application
20240008461
A computer readable ASCII file entitled “HLPCTP20230201217-sequence_listing.txt”, that was created on May 4, 2023, with a file size of about 6,743 bytes, contains the sequence listing for this application, has been filed with this application, and is hereby incorporated by reference in its entirety.
The present disclosure relates to a breeding method of Carassius auratus strain without intermuscular bones, belonging to the technical field of aquaculture breeding methods.
Cyprinid is one of the main aquaculture fish in China, with an annual output of about 20 million tons in China, providing nearly ⅓ of the high-quality animal protein for the Chinese people. However, because of lots of intermuscular bones in cyprinid fishes, it is inconvenient for people to eat, and may even lead to physical injuries such as getting stuck in the throat. At the same time, the processing of fish products (such as fish balls, etc.) is also hindered. Therefore, the genetic improvement of intermuscular bones in cyprinid fishes has become one of the most important targets of aquaculture genetic breeding.
At present, there are some reports on selection and breeding of intermuscular bones. For example, Xiao-feng Xu et al.[1] found a normally grown and developed intermuscular bone-deficient mutant in the gynogenetic group of grass carp, but no mutant population of grass carp with intermuscular bone-deficient or less intermuscular bone was obtained as reported. Brazilian scientists[2] screened a population lacking intermuscular bones in Colossoma macropomum using X-rays, but no population with less intermuscular bone or intermuscular bone-deficient in the subsequent breeding program was obtained[3]. Guo et al.[4] conducted a hybrid experiment between Megalobrama terminalis♀ and Culter alburnus♂, and showed that the number of intermuscular bones (127) in the hybrid progeny of Megalobrama terminalis♀ and Culter alburnus♂ was smaller than that of the male parent (137), greater than that of the female parent (124), but significantly fewer than the number of intermuscular bones in the hybrid progeny (133) of Megalobrama amblycephala♀ and Culter alburnus♂, which indicated that varieties with less intermuscular bones could be obtained by hybrid breeding methods, and an invention patent (publication number of CN107347747A) was applied then. Li Ling et al.[5] reported that the number of intermuscular bones in the artificial cultivation of hybrid Carassius auratus was less than that of the wild Carassius auratus, and the number of intermuscular bones in the Carassius auratus could be reduced by artificial cultivation and hybrid breeding. Bao-long Bao et al. invented a method for thicking the intermuscular bones by knocking out the MSTN gene[9-12]. By knocking out the scxa gene in zebrafish (Danio rerio), Gao Zexia et al. obtained mutants with more than 70% reduction of the number of intermuscular bones, but also caused dysplasia of other bones such as ribs[6-8], and the applications in other Cyprinoid fish has not been reported. In conclusion, although there are some methods to reduce the number of intermuscular bones in cyprinid fish, there is still no new variety/strain without intermuscular bones.
Crucian carp (Carassius auratus) is one of the main aquaculture varieties in China, with an annual production of about 3 million tons. Its meat is delicious and popular among people. At the same time, the quality of Carassius auratus has been affected due to the intermuscular bones (the average number of intermuscular bones in different varieties of Carassius auratus is about 71 to 84), thus, intermuscular bones are also an important target for their genetic breeding. Although it has been reported that the number of intermuscular bones in Carassius auratus can be reduced by hybrid breeding and artificial selection, no strain or variety with more than 50% reduction in the number of intermuscular bones has been found.
In order to perform genetic improvement of intermuscular bones in Carassius auratus, the present disclosure proposes a method for breeding Carassius auratus with fewer intermuscular bones or without intermuscular bones by knocking out the bmp6 gene.
The method for breeding Carassius auratus strains without intermuscular bones of the present disclosure carries out the breeding of the Carassius auratus strain without intermuscular bones according to the following steps:
Designing knockout target sites for two copies of bmp6 gene in the Carassius auratus genome, bmp6a and bmp6b, respectively, and then obtaining F2 generation individuals from a homozygous line with bmp6a and bmp6b double gene mutation through two rounds of gene knockout and screening, and then using the F2 generation individuals from the homozygous line with bmp6a and bmp6b double gene mutation to propagate to form a new Carassius auratus strain without intermuscular bone;
Among them, mixing the sgRNA corresponding to (bmp6a), (bmp6b) or (bmp6a and bmp6b) with Cas9 protein and microinjecting a mixture obtained into Carassius auratus embryos in the single cell stage, to perform the first round of gene knockout to construct the F0 generation population, culturing the F0 generation population for 3 to 5 months followed by PIT labeling and DNA extraction, then sequencing to determine the alleles and mutation rates of somatic mutations of Carassius auratus, selecting the F0 generation individuals with the somatic mutation rate of more than 95% as parents to prepare 0-generation fertilized eggs;
Mixing the sgRNAs corresponding to (bmp6a), (bmp6b) or (bmp6a and bmp6b) with Cas9 protein and microinjecting a mixture obtained into 0-generation fertilized eggs to perform the second round of gene knockout to construct the F1 generation population, culturing the F1 generation population for 3 to 5 months followed by PIT labeling and DNA extraction, then sequencing to determine the alleles and mutation rates of somatic mutations of Carassius auratus, selecting the F1 generation individuals from a somatic bmp6a and bmp6b double gene mutant line with the somatic mutation rate of more than 95% as parents for reproduction to construct F2 generation, then selecting F2 generation individuals from a homozygous line with bmp6a and bmp6b double gene mutation.
Carassius auratus varieties with less than 20 intermuscular bones and without intermuscular bones are obtained by the method of the present disclosure.
Since the Carassius auratus genome has undergone a fourth round of genome duplication event[13], there are two copies of the bmp6 gene in the Carassius auratus genome.
The present disclosure is further described in detail below in conjunction with examples. The following examples are intended to illustrate the present disclosure, but not to limit the scope herein.
The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, methods and instruments used, unless otherwise specified, are conventional materials, reagents, methods and instruments in the art, which are commercially available to those skilled in the art.
Embodiment 1: The breeding method of Carassius auratus strain without intermuscular bones of the present embodiment:
The target sites are designed to knock out two copies of bmp6 gene in the Carassius auratus genome, bmp6a and bmp6b, respectively, and then F2 generation individuals from a homozygous line with bmp6a and bmp6b double gene mutation are obtained through two rounds of gene knockout and screening, and then the F2 generation individuals from the homozygous line with bmp6a and bmp6b double gene mutation are propagated to form a new Carassius auratus strain without intermuscular bone;
Among them, the sgRNAs corresponding to (bmp6a), (bmp6b) or (bmp6a and bmp6b) are mixed with Cas9 protein, and the obtained mixture is microinjected into Carassius auratus embryos in the single cell stage, the first round of gene knockout is performed to construct the F0 generation population, and then the F0 generation population is cultured for 3 to 5 months followed by PIT labeling and DNA extraction then the alleles and mutation rates of somatic mutations of Carassius auratus are determined by sequencing, and the F0 generation individuals with the somatic mutation rate of more than 95% are selected as parents to prepare 0-generation fertilized eggs;
The sgRNAs corresponding to (bmp6a), (bmp6b) or (bmp6a and bmp6b) are mixed with Cas9 protein, and the obtained mixture is microinjected into 0-generation fertilized eggs, the second round of gene knockout is performed to construct the F1 generation population, and then the F1 generation population is cultured for 3 to 5 months followed by PIT labeling and DNA extraction, then the alleles and mutation rates of the somatic mutations of Carassius auratus are determined by sequencing, and the F1 generation individuals from a somatic bmp6a and bmp6b double gene mutant line with the somatic mutation rate of more than 95% are selected as parents for reproduction to construct an F2 generation, then F2 generation individuals from a homozygous line with bmp6a and bmp6b double gene mutation are selected.
Among them, the DNA extraction and sequencing method is as follows: 100 μL of lysis solution is added (the lysis solution comprises 0.5 mg/mL proteinase K, 10 mM Tris (pH 8.0), 50 mM KCl, 0.3% Tween 20, 0.3% NP40) to 0.3-0.5cm2 fin clip samples; the lysis methods is: the PCR instrument is set at 55° C. for 6 h, 98° C. for 10 min for lysis; after lysis, the obtained product is mixed well, then centrifuged at 1000-2000 rpm for 2 min, and the supernatant is taken as a PCR amplification template.
PCR amplification: 2 pairs of primers are used for PCR amplification, of which, 1 pair of primers is the target site primers (the primer sequences used to amplify the target fragment are shown in Table 2 and concatenated by the M13 universal primer sequence at 5′ end), and the other pair of primers is index primers (the M13 universal primer sequence and the index base sequence at the 5′ end used to identify the sample). A two-step PCR amplification is performed. The PCR amplification volume in the first step is 10 L, including 1 μL of genomic DNA supernatant, 0.5 μL of 1 μM forward and reverse target primers, and 5 μL of 2×Dream Taq Master Mix (Thermo Fisher, CA, USA), the volume is supplemented to 10 μL with enzyme-free water; PCR program: 95° C. for 3 min; 10 cycles of 95° C. for 30 s, 60° C. for 30 s and 72° C. for 30 s; 72° C. for 2 min; PCR amplification in step 2 is that 0.5 μL of 5 μM forward and reverse index primers are added to the PCR amplification product obtained in step 1, the PCR program is set to 95° C. for 2 min; 6 cycles of 95° C. for 30 s, 58° C. for 30 s and 72° C. for 30 s; 15 cycles of 95° C. for 30 s, 72° C. for 30 s; 72° C. for 2 min.
After PCR amplification, the PCR products are mixed in equal amounts, and a DNA sequencing library is constructed with the TrueSeq Sample Preparation Kit, and is sequenced using Illumina MiSeq sequencing platform with 300 bp Pair-End mode. The data obtained by high-throughput sequencing are first used to identify amplification loci and samples using the method described by Tong et al.[14]. The sequenced data of each sample in each PCR product is analyzed using the CRISPResso2[15] program to determine the alleles and mutation rates of somatic mutations.
Among them, Sanger sequencing is used for mutant detection: PCR amplification is performed on the samples using the primers shown in Table 2, and the volume is set to 25 μL: 2 μL of genomic DNA supernatant, 1 μL of 10 μM forward and reverse target primers, 12.5 μL of 2×Dream Taq Master Mix (Thermo Fisher, CA, USA), the volume is supplemented to 25 μL with enzyme-free water; PCR program is 95° C. for 3 min; 35 cycles of 95° C. for 30 s, 60° C. for 30 s, 72° C. for 30 s; 72° C. for 5 min. PCR products are detected by 1.5% agarose gel electrophoresis. After detection, the products are purified and recovered, TA clone is performed, 2 μL of PCR products are taken after colony PCR amplification, and detected with 8% polypropylene, and the colonies with different band sizes from the control are selected for Sanger sequencing.
Embodiment 2: The difference between this embodiment and Embodiment 1 is that the knockout target sites of the bmp6 gene are shown in Table 1 in this embodiment.
Others are the same as Embodiment 1.
Embodiment 3: The difference between this embodiment and Embodiment 1 or 2 is that: the sgRNA forward primer shown in Table 1 and the sgRNA reverse primer with the sequence of 5′-GATCCGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTT ATTTTAACTTGCTATTTCTAGCTCTAAAAC-3′ (SEQ ID NO:31) are used to synthesize sgRNA in vitro. The sgRNA synthesis volume in vitro is: 2.5 μL of 10 μM sgRNA forward and reverse primers, 25 μL of 2×Dream Taq Master Mix (ThermoFisher, CA, USA), and sgRNA synthesis volume is supplemented to 50 μL with enzyme-free water; a total of 100 μL is amplified in 2 tubes. The sgRNA synthesis procedure in vitro is: denaturation at 95° C. for 3 min, followed by 30 cycles of 95° C. for 30 s, 58° C. for 30 s, 72° C. for 30 s; extension at 72° C. for 5 min; then the obtained amplified product is purified and recovered, followed by an in vitro transcription, and 30 μL of reaction volume is established for each target site: 1 μg of sgRNA PCR recovered product, 10 μL of NTP Buffer Mix, 2 μL of T7 RNA Polymerase Mix, the reaction volume is supplemented to 30 μL with enzyme-free water; transcription was performed at 37° C. for 4 h, 20 μL of enzyme-free water is added after the reaction, and 2μL of DNase I was added after mixing. Digestion at 37° C. for 15 min to remove DNA. Others are the same as the embodiments 1 or 2.
The in vitro PCR products of sgRNA are detected by 1.5% agarose gel electrophoresis, and the length of products is 120 bp. After detection, the PCR products are purified and recovered with a PCR product purification and recovery kit (Exygen), and the concentration is determined with a Qubit 3 kit (Thermo Fisher, CA, USA) for use. The recovery concentration of sgRNA PCR products is in a range of 100 to 160 ng/μL.
The in vitro transcribed sgRNAs are purified and recovered with an RNA purification kit (Qiagen). The concentration of the recovered product is determined by using a Qubit 3 kit (Thermo Fisher, CA, USA) and the recovered product is stored in a −80 ° C. refrigerator until use. The recovery concentration of in vitro transcribed sgRNA is in a range of 800 to 3000 ng/μL.
Embodiment 4: The difference between this embodiment and Embodiment 1 or 2 or 3 is that the microinjection method in this embodiment is: the sgRNA synthesized in vitro and Cas9 protein (NEB M0646, MA, USA) are mixed in a molar ratio of 3:1, a mixture obtained is incubated at room temperature for 10 min, then 25% phenol red is added, and the obtained product is injected into Carassius auratus embryos in the single cell stage; among them, the target site sgRNAs on each exon are mixed in equal amounts and injected with a final concentration no less than 50 ng/μL of each sgRNA, the control group is injected with 25% phenol red, and the injection volume of each fertilized egg is 1 nL±0.02 nL. Others are the same as the Embodiment 1, 2 or 3.
Breeding method of Carassius auratus strain without intermuscular bone: The target sites were designed to knock out the two copies of bmp6 gene in the Carassius auratus genome, bmp6a and bmp6b, respectively, and then F2 generation individuals from a homozygous line with bmp6a and bmp6b double gene mutation were obtained through two rounds of gene knockout and screening, and then the F2 generation individuals from the homozygous line with bmp6a and bmp6b double gene mutation were propagated to form a new Carassius auratus strain without intermuscular bones;
Among them, the sgRNAs corresponding to (bmp6a), (bmp6b) or (bmp6a and bmp6b) were mixed with Cas9 protein, and the obtained mixture was microinjected into Carassius auratus embryos in the single cell stage, the first round of gene knockout was performed to construct the F0 generation population, and then the F0 generation population was cultured for 3 to 5 months followed by PIT labeling and DNA extraction, then the alleles and mutation rates of somatic mutations of Carassius auratus was determined by sequencing, and the F0 generation individuals with the somatic mutation rate of more than 95% were selected as parents to prepare 0-generation fertilized eggs;
The sgRNAs corresponding to (bmp6a), (bmp6b) or (bmp6a and bmp6b) were mixed with Cas9 protein, and the obtained mixture was microinjected into the 0-generation fertilized eggs, the second round of gene knockout was performed to construct the F1 generation population, and then the F1 generation population was cultured for 3 to 5 months followed by PIT labeling and DNA extraction, then the alleles and mutation rates of the somatic mutations of Carassius auratus were determined by sequencing, and the F1 generation individuals from a somatic bmp6a and bmp6b double gene mutant line with the somatic mutation rate of more than 95% were selected as parents for reproduction to construct a F2 generation, then F2 generation individuals from a homozygous line with bmp6a and bmp6b double gene mutation were selected.
Among them, the DNA extraction and sequencing method was as follows: 100 μL of lysis solution was added (the composition of the lysate is 0.5 mg/mL proteinase K, 10 mM Tris (pH 8.0), 50 mM KCl, 0.3% Tween 20, 0.3% NP40) to 0.3-0.5 cm2 fin clip samples; the lysis methods was: the PCR instrument was set at 55° C. for 6 h, 98° C. for 10 min for lysis; after lysis, the obtained product was mixed well, then centrifuged at 1000-2000 rpm for 2 min, and the supernatant was taken as the PCR amplification template. PCR amplification: 2 pairs of primers were used for PCR amplification, of which, 1 pair of primers was the target site primers (the primer sequences used to amplify the target fragment as shown in Table 2 and the 5′-end M13 universal primer sequence), and the other pair of primers were index primers (the M13 universal primer sequence and the index base sequence at the 5′ end used to identify the sample). PCR amplification was performed in 2 steps. The PCR amplification volume in the first step was 10 μL, including 1 μL of genomic DNA supernatant, 0.5 μL of 1 μM forward and reverse target primers, and 50 μL of 2×Dream Taq Master Mix (Thermo Fisher, CA, USA), the volume was supplemented to 10 μL with enzyme-free water; PCR program: 95° C. for 3 min; 10 cycles of 95° C. for 30 s, 60° C. for 30 s and 72° C. for 30 s; 72° C. for 2 min; PCR amplification in step 2 is that 0.5 μL of 5 μM forward and reverse index primers were added to the PCR amplification product obtained in step 1, the PCR program was set to 95° C. for 2 min; 6 cycles of 95° C. for 30 s, 58° C. for 30 s and 72° C. for 30 s; 15 cycles of 95° C. for 30 s, 72° C. for 30 s; 72° C. for 2 min. After PCR amplification, the PCR products were mixed in equal amounts, and a DNA sequencing library was constructed with the TrueSeq Sample Preparation Kit, and was sequenced by using Illumina MiSeq sequencing platform with 300 bp Pair-End mode. The data obtained by high-throughput sequencing were first used to identify amplification loci and samples using the method described by Tong et al (Tong et al. 2018). The sequenced data of each sample in each PCR product was analyzed using the CRISPResso2 (Fiume et al. 2019) program to determine the alleles and mutation rates of somatic mutations.
Among them, Sanger sequencing was used for mutant detection: PCR amplification was performed on the samples using the primers shown in Table 2, and the system was set to 25 μL: 2 μL of genomic DNA supernatant, 1 μL of 10 μM forward and reverse target primers, 12.5 μL of 2×Dream Taq Master Mix (Thermo Fisher, CA, USA), the volume was supplemented to 25 μL with enzyme-free water; PCR program was 95° C. for 3 min; 35 cycles of 95° C. for 30 s, 60° C. for 30 s, 72° C. for 30 s; 72° C. for 5 min. PCR products were detected by 1.5% agarose gel electrophoresis. After detection, the products were purified and recovered, TA clone was performed, 2 μL of PCR products were taken after colony PCR amplification, and detected with 8% polypropylene, and the colonies with different size bands from the control were selected for Sanger sequencing.
Among them, the knockout target sites of the bmp6 gene were shown in Table 1.
The sgRNA forward primer was shown in Table 1 and the sgRNA reverse primer with the sequence of 5′-GATCCGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTT ATTTTAACTTGCTATTTCTAGCTCTAAAAC-3′ (SEQ ID NO:31) were used to synthesize sgRNA in vitro. The sgRNA synthesis volume in vitro was: 2.5 μL of 10 μM sgRNA forward and reverse primers, 25 μL of 2×Dream Taq Master mix (Thermo Fisher, CA, USA), the volume was supplemented to 50 μL with enzyme-free water; a total of 100 μL was amplified in 2 tubes. The sgRNA synthesis procedure in vitro was: denaturation at 95° C. for 3 min, followed by 30 cycles of 95° C. for 30 s, 58° C. for 30 s, 72° C. for 30 s; extension at 72° C. for 5 min; then the obtained amplified product was purified and recovered, followed by an in vitro transcription, and 30 μL of reaction volume was established for each target site: 1 μg of sgRNA PCR recovered product, 10 μL of NTP Buffer Mix, and 2 μL of T7 RNA Polymerase Mix, the volume was supplemented to 30 μL with enzyme-free water; transcription was performed at 37° C. for 4 h, 20 μL of enzyme-free water was added after the reaction, and 2 μL of DNase I was added after mixing. Digestion at 37° C. for 15 min to remove DNA.
In vitro sgRNA PCR products were detected by 1.5% agarose gel electrophoresis, and the length of products was 120 bp. After detection, the sgRNA PCR products were purified and recovered with a PCR product purification and recovery kit (Exygen), and the concentration was determined with a Qubit 3 kit (Thermo Fisher, CA, USA) for use. The recovery concentration of the sgRNA PCR products was in a range of 100 to 160 ng/μL.
The in vitro transcribed sgRNAs were purified and recovered with an RNA purification kit (Qiagen). The concentration of the recovered product was determined by using a Qubit 3 kit (Thermo Fisher, CA, USA) and the recovered product was stored in a −80 ° C. refrigerator until use. The recovery concentration of in vitro transcribed sgRNA was in a range of 800 to 3000 ng/μL.
The microinjection method was as follows: sgRNA synthesized in vitro and Cas9 protein (NEB M0646, MA, USA) were mixed at a molar concentration ratio of 3:1, a mixture obtained was incubated at room temperature for 10 min, then 25% phenol red was added, and the obtained product was injected into Carassius auratus embryos in the single cell stage; among them, the target site sgRNAs on each exon were mixed in equal amounts and injected with a final concentration no less than 50 ng/μL of each sgRNA, the control group was injected with 25% phenol red, and the injection volume of each fertilized egg is 1 nL±0.02 nL.
The diploid Carassius auratus used in this example came from the Hulan Experiment Station of the Heilongjiang River Fisheries Research Institute, Chinese Academy of Fishery Sciences. The parents fish were cultured in a 700 m2 fish pond, and were injected with oxytocin drugs (4 μg/kg luteinizing releasing hormone analogue, LRH-A2; 1 mg/k DOM, 100 units/kg chorionic gonadotropin HCG) for spawn. After artificial fertilization, the obtained fertilized eggs were incubated in a hatching tank of 24 cm×20 cm×24 cm, and the hatching water temperature was 22° C.-23° C. After hatching, larvae were fed with Artemia salina 4 times/d after the yolk was absorbed. The larvae were moved to an outdoor 500 m2 pond to culture when they were cultured in a hatching tank to the size of 2 cm-3 cm. Artificial diet was fed in the fish fingerling breeding stage, 2 times/d.
The bones of the new Carassius auratus strain with intermuscular bone-deficient in this example were observed by bone-staining, and it was found that the intermuscular bones were completely deficient in 5 samples, and the number of intermuscular bones in 4 samples was only 4 to 20 (as shown in
Although the present disclosure has been described in detail through the above example, it is only a part of embodiments of the present disclosure, rather than all embodiments. People can also obtain other embodiments according to the present embodiment without creativity. These embodiments all fall within the claimed scope of the present disclosure.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202110478410.7 | Apr 2021 | CN | national |
This application is a national stage application of International Patent Application No. PCT/CN2022/070608, filed on Jan. 7, 2022, which claims the priority of Chinese Patent Application No. 202110478410.7, entitled “Crucian carp (Carassius auratus) strain without intermuscular bones and breeding method thereof” filed in China National Intellectual Property Administration on Apr. 30, 2021, both of which are incorporated by reference herein in its entirety as part of the present application.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2022/070608 | 1/7/2022 | WO |
